Ozempic
Weekly subcutaneous injectionType 2 diabetes; label includes cardiovascular and kidney risk-reduction claims in specified populations.
Find official label ↗Loading scientific anatomy…
Interactive anatomy · drag to rotate02 · Consumer names
One ingredient.
Distinct products.
Wegovy
Weekly subcutaneous injectionChronic weight management and specified cardiovascular/MASH uses.
Find official label ↗Rybelsus
Daily oral tabletType 2 diabetes; formulation and instructions differ from injectable products.
Find official label ↗Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label
03 · Mechanism + use
What the molecule does,
and where the label stops.
- What it does
- Activates GLP-1 receptors, increasing glucose-dependent insulin secretion, reducing glucagon, lowering energy intake through appetite pathways, and delaying early postprandial gastric emptying.Mechanism source
- Labeled-use boundary
- Indications are product-specific. The ingredient should never be treated as one interchangeable dosing record across Ozempic, Wegovy, and Rybelsus.Primary label
04 · Labeled safety
Risk belongs
beside benefit.
Boxed warning
Injectable semaglutide labels warn about thyroid C-cell tumors observed in rodents; human relevance is unknown.Open boxed warning
Who should avoid it
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Serious hypersensitivity to semaglutide or product excipients
Important serious risks
- Acute pancreatitis
- Gallbladder disease
- Acute kidney injury from volume depletion
- Diabetic retinopathy complications in susceptible patients
- Severe gastrointestinal reactions
This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.
05 · Evidence interpretation
Claims with
their edges visible.
Weight and metabolic outcomes
Multiple randomized programs measured weight and glycemic endpoints across distinct populations and doses.
Supporting source- Evidence form
- Large randomized trial programs
- Keep in view
- Effects cannot be transferred between products, doses, or populations without checking the study and label.
Cardiovascular and kidney outcomes
Event-driven outcomes trials support selected product-specific indications.
Supporting source- Evidence form
- Randomized outcomes evidence
- Keep in view
- Risk reduction applies to the enrolled populations and labeled product.
Safety is formulation-aware
The label integrates trial adverse events, warnings, interactions, and postmarketing reports.
Supporting source- Evidence form
- Regulatory synthesis
- Keep in view
- Spontaneous reports cannot establish incidence or causality.
06 · Research universe
Reviewed anchors.
Live indexes.
The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.
- 01Regulatory labelWegovy prescribing informationOpen source ↗
Current DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
- 02Regulatory labelOzempic prescribing informationOpen source ↗
Current DailyMed label for Ozempic; a separate product record from Wegovy and Rybelsus.
- 03Literature indexEvery PubMed result for semaglutideOpen source ↗
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
- 04Trial registryEvery registered study for semaglutideOpen source ↗
Live ClinicalTrials.gov search, including completed, active, and historical records.
- 05Chemical recordsemaglutide chemical recordOpen source ↗
PubChem compound search from the National Library of Medicine.